5-HT2A receptor explained

The 5-HT2A receptor is a subtype of the 5-HT2 receptor that belongs to the serotonin receptor family and functions as a G protein-coupled receptor (GPCR).[1] It is a cell surface receptor[2] that activates multiple intracellular signalling cascades.[3] Like all 5-HT2 receptors, the 5-HT2A receptor is coupled to the Gq/G11 signaling pathway. It is the primary excitatory receptor subtype among the serotonin-responsive GPCRs. The 5-HT2A receptor was initially noted for its central role as the primary target of serotonergic psychedelic drugs such as LSD and psilocybin mushrooms. It later regained research prominence when found to mediate, at least in part, the effects of many antipsychotic drugs, particularly atypical antipsychotics.

History

The serotonin receptors were split into two classes by John Gaddum and Picarelli in 1957 when it was discovered that some of the serotonin-induced changes in the gut could be blocked by morphine, while the remainder of the response was inhibited by dibenzyline (phenoxybenzamine), leading to the naming of M and D receptors, respectively.[4] The 5-HT2A receptor is thought to correspond to what was originally described as D subtype of serotonin receptors by Gaddum and Picarelli.[5]

In the era before molecular cloning, when radioligand binding and displacement was the only major tool, spiperone and LSD were shown to label two different 5-HT receptors, and neither of them displaced morphine, leading to naming of the 5-HT1, 5-HT2 and 5-HT3 receptors, corresponding to high affinity sites from LSD, spiperone and morphine, respectively.[6] Later, it was shown that the 5-HT2 receptor was very close to the 5-HT1C receptor and they were thus were grouped together, renaming the 5-HT2 receptor into 5-HT2A receptor and the 5-HT1C receptor into the 5-HT2C receptor. Thus, the 5-HT2 receptor family is composed of three separate molecular entities: the 5-HT2A (formerly known as 5-HT2 or D), the 5-HT2B (formerly known as 5-HT2F) and the 5-HT2C (formerly known as 5-HT1C) receptors.[7]

The serotonin 5-HT2A receptor was identified via radioligand binding in 1978 by Leysen and colleagues.[8] [9] Peroutka and Snyder identified two distinct serotonin receptors and named them the 5-HT1 receptor and 5-HT2 receptor in 1979.[10] [11] Later, both of these receptors were found to have several subtypes, including the serotonin 5-HT2A receptor. The serotonin 5-HT2A receptor was characterized as a membrane protein by Wouters and colleagues in 1985.[12] The gene encoding the rat serotonin 5-HT2A receptor, HTR2A, was cloned in 1988 by Pritchett and colleagues.[13] The human gene was cloned by Branchek and colleagues in 1990.[14]

Gene

The 5-HT2A receptors is coded by the HTR2A gene. In humans the gene is located on chromosome 13. The gene has previously been called just HTR2 until the description of two related genes HTR2B and HTR2C. Several interesting polymorphisms have been identified for HTR2A: A-1438G (rs6311), C102T (rs6313), and His452Tyr (rs6314). Many more polymorphisms exist for the gene. A 2006 paper listed 255.[15]

Probable role in fibromyalgia as the T102C polymorphisms of the gene 5HT2A were common in fibromyalgia patients.[16]

Human HTR2A gene is thought to consist of 3 introns and 4 exons and to overlap with human gene HTR2A-AS1 which consists of 18 exons.[17] There are over 200 organisms that have orthologs with the human HTR2A. Currently, the best documented orthologs for HTR2A gene are the mouse,[18] and zebrafish.[19] There are 8 paralogs for the HTR2A gene. The HTR2A gene is known to interact and activate G-protein genes such as GNA14, GNAI1, GNAI3, GNAQ, and GNAZ.[20] These interactions are critical for cell signaling[21] [22] and homeostasis[23] in many organisms.[24]

In human brain tissue, regulation of HTR2A varies depending on the region: frontal cortex, amygdala, thalamus, brain stem and cerebellum. In a paper from 2016, they found that HTR2A undergoes a variety of different splicing events, including utilization of alternative splice acceptor sites, exon skipping, rare exon usage, and intron retention.

Transcriptional regulation

There are a few mechanisms of regulation for HTR2A gene such regulated by DNA methylation at particular transcript binding sites.[25] [26] Another mechanism for the correct regulation of gene expression is achieved through alternative splicing. This is a co-transcriptional process, which allows the generation of multiple forms of mRNA transcript from a single coding unit and is emerging as an important control point for gene expression. In this process, exons or introns can be either included or excluded from precursor-mRNA resulting in multiple mature mRNA variants.[27] These mRNA variants result in different isoforms which may have antagonistic functions or differential expression patterns, yielding plasticity and adaptability to the cells.[28] One study found that the common genetic variant rs6311 regulates expression of HTR2A transcripts containing the extended 5' UTR.

Tissue distribution

5-HT2A is expressed widely throughout the central nervous system (CNS).[29] It is expressed near most of the serotonergic terminal rich areas, including neocortex (mainly prefrontal, parietal, and somatosensory cortex) and the olfactory tubercle . Especially high concentrations of this receptor on the apical dendrites of pyramidal cells in layer V of the cortex may modulate cognitive processes, working memory, and attention[30] [31] [32] by enhancing glutamate release followed by a complex range of interactions with the 5-HT1A,[33] GABAA,[34] adenosine A1,[35] AMPA,[36] mGluR2/3,[37] mGlu5,[38] and OX2 receptors.[39] [40] In the rat cerebellum, the protein has also been found in the Golgi cells of the granular layer,[41] and in the Purkinje cells.[42] [43]

In the periphery, it is highly expressed in platelets and many cell types of the cardiovascular system, in fibroblasts, and in neurons of the peripheral nervous system. Additionally, 5-HT2A mRNA expression has been observed in human monocytes.[44] Whole-body distribution of the 5-HT2A/2C receptor agonist, [11C]Cimbi-36 show uptake in several internal organs and brown adipose tissue (BAT), but it is not clear if this represents specific 5-HT2A receptor binding.[45]

Structure

The 5-HT2A receptor is a member of the class A (rhodopsin-like) G protein-coupled receptor (GPCR) family, characterized by seven transmembrane α-helices connected by extracellular and intracellular loops.[46] Its ligand-binding pocket is composed of two adjacent subpockets: the orthosteric binding pocket (OBP) and an extended binding pocket (EBP), with a unique side-extended cavity near the orthosteric site that distinguishes it from related receptors.[47] [48] Ligands are anchored primarily through a conserved aspartate residue (D155^3.32) that interacts with their charged amine groups, while additional interactions involve hydrophobic contacts and hydrogen bonds with residues in both the OBP and EBP.[49] Structural studies reveal that the receptor undergoes significant conformational changes upon activation, particularly in transmembrane helices 3 and 6, which facilitate G protein coupling and signal transduction.[50] The extracellular ligand-binding pocket is closed by a flexible "lid," and the intracellular region includes a short helix (H8) stabilized by π-stacking interactions, both of which contribute to the receptor's dynamic conformational landscape. These structural features underlie the receptor's ability to recognize diverse ligands and mediate complex signaling behaviors.

The cryo-EM structures of the serotonin 5-HT2A receptor with a variety of serotonin 5-HT2A receptor agonists, including the tryptamines serotonin (neurotransmitter and endogenous agonist), psilocin (psychedelic), and dimethyltryptamine (DMT) (psychedelic), the lysergamides LSD (psychedelic) and 2-bromo-LSD (BOL-148) (non-hallucinogenic), and the phenethylamines mescaline (psychedelic) and RS130-180 (β-arrestin-biased agonist with unknown hallucinogenic potential), have been solved and published by Bryan Roth and colleagues.[51] [52]

Function

The 5-HT2A receptor is a subtype of serotonin receptor that plays a critical role in the central nervous system, particularly in regions involved in cognition, learning, and memory.[53] It is highly expressed in the cerebral cortex, especially in layer V pyramidal neurons and certain interneurons, where it modulates thalamocortical information processing and may influence gamma oscillations, which are important for sensory integration and perception. Functionally, the 5-HT2A receptor is a G protein-coupled receptor (GPCR) that primarily signals through the phospholipase C (PLC) pathway, leading to the production of inositol triphosphate (IP3) and diacylglycerol, but it can also activate other signaling cascades such as arachidonic acid and 2-arachidonylglycerol pathways. Notably, the receptor exhibits "functional selectivity," meaning different ligands can differentially activate these signaling pathways, which is relevant for the distinct effects of hallucinogens, antipsychotics, and antidepressants that target the receptor.[54] Activation of the 5-HT2A receptor by agonists is associated with enhanced cognition and hallucinogenic effects, while antagonists have antipsychotic and antidepressant properties. Dysregulation of 5-HT2A receptor function has been implicated in psychiatric disorders such as depression, schizophrenia, and drug addiction. Additionally, the receptor undergoes unique regulatory processes, including desensitization and internalization that are partly independent of β-arrestin, further distinguishing it from other GPCRs and influencing its response to long-term pharmacological modulation.

Signaling cascade

The 5-HT2A receptor is known primarily to couple to the Gαq signal transduction pathway. Upon receptor stimulation with agonist, Gαq and β-γ subunits dissociate to initiate downstream effector pathways. Gαq stimulates phospholipase C (PLC) activity, which subsequently promotes the release of diacylglycerol (DAG) and inositol triphosphate (IP3), which in turn stimulate protein kinase C (PKC) activity and Ca2+ release.[55]

Effects

Physiological processes mediated by the receptor include:

Ligands

Agonists

See also: List of miscellaneous 5-HT2A receptor agonists.

Activation of the 5-HT2A receptor is necessary for the effects of the "classic" psychedelics like LSD, psilocin and mescaline, which act as full or partial agonists at this receptor, and represent the three main classes of 5-HT2A agonists, the ergolines, tryptamines and phenethylamines, respectively. A very large family of derivatives from these three classes has been developed, and their structure-activity relationships have been extensively researched.[69] [70] Agonists acting at 5-HT2A receptors located on the apical dendrites of pyramidal cells within regions of the prefrontal cortex are believed to mediate hallucinogenic activity. Some findings reveal that psychoactive effects of classic psychedelics are mediated by the receptor heterodimer 5-HT2A–mGlu2 and not by monomeric 5-HT2A receptors.[71] [72] However, newer research suggests that 5HT2A and mGlu2 receptors do not physically associate with each other, so the former findings have questionable relevance.[73] Agonists enhance dopamine in PFC, enhance memory and play an active role in attention and learning.[74] [75]

Serotonin 5-HT2A receptor agonists include serotonergic psychedelics[76] and non-hallucinogenic agents.[77] [78] Psychedelics have widely been encountered as recreational drug or drugs of misuse, with potential clinical consequences such as overdose, hospitalization, bad trips and worsened mental health, and rare adverse effects such as seizures, psychosis, and hallucinogen persisting perception disorder (HPPD).[79] [80] On the other hand, psychedelics and non-hallucinogenic serotonin 5-HT2A receptor agonists are under development as novel treatments for psychiatric disorders like depression, anxiety, and addiction as well as other conditions like cluster headaches.[81] [82] [83] [84] [85] Both psychedelics and non-hallucinogenic serotonin 5-HT2A receptor agonists are claimed to act as psychoplastogens and this might be involved in their therapeutic effects.[86] [87]

Anti-inflammatory effects

Various serotonergic psychedelics, acting as serotonin 5-HT2A receptor agonists, have been found to be highly potent and efficacious anti-inflammatory and immunomodulatory agents in preclinical research (i.e., animal and in-vitro studies).[88] [89] [90] [91] [92] [93] [94] In contrast to corticosteroids however, psychedelics with anti-inflammatory effects do not appear to suppress the immune system. Some psychedelics have been found to be far more potent in their anti-inflammatory effects than in their psychedelic effects. For instance, (R)-DOI is 30- to >50-fold more potent in producing anti-inflammatory effects than in producing psychedelic-like behavioral effects in animal research. Psilocin, the active form of psilocybin, has similar anti-inflammatory potency as (R)-DOI.

The potencies of psychedelics and other serotonin 5-HT2A receptor agonists as anti-inflammatory drugs vary, with 2C-I, DOIB, 2C-B, 4-HO-DiPT, DOI, 2,5-DMA, DOET, DOM, psilocin, and 2C-H being highly potent and fully efficacious anti-inflammatories; TMA-2, 2C-B-Fly, TCB-2, ETH-LAD, LSD, and 2C-T-33 being partially efficacious anti-inflammatories; and lisuride, 1-methylpsilocin, 5-MeO-DMT, and DMT having negligible efficacy. Both non-hallucinogenic agents with full anti-inflammatory effects, such as 2,5-DMA, and non-anti-inflammatory agents with full psychedelic effects, such as DOTFM, are known.[95] [96] Hence, the psychedelic and anti-inflammatory effects of serotonin 5-HT2A receptor agonists appear to be fully dissociable. These effects appear to be mediated by different intracellular signaling pathways, although the exact pathways are unclear.

Serotonin 5-HT2A receptor agonists with anti-inflammatory effects but reduced psychedelic effects, such as 2C-iBu (ELE-02), are under development for the potential treatment of inflammatory conditions.[97] [98] [99] They may also have applications in the treatment of neuroinflammation. The anti-inflammatory effects of psychedelics might be involved in the claimed effects of psychedelic microdosing.[100] [101] Relatedly, LSD microdosing is being studied in the treatment of Alzheimer's disease specifically for its anti-inflammatory effects.[102] [103]

Full agonists

Partial agonists

Selective agonists

Peripherally selective agonists

One effect of 5-HT2A receptor activation is a reduction in intraocular pressure, and so 5-HT2A agonists can be useful for the treatment of glaucoma. This has led to the development of compounds such as AL-34662 that are hoped to reduce pressure inside the eyes but without crossing the blood–brain barrier and producing hallucinogenic side effects.[141] Animal studies with this compound showed it to be free of hallucinogenic effects at doses up to 30 mg/kg, although several of its more lipophilic analogues did produce the head-twitch response known to be characteristic of hallucinogenic effects in rodents.[142]

Antagonists

Serotonin 5-HT2A receptor antagonists, including many atypical antipsychotics, more selective agents like pimavanserin, and certain antidepressants and hypnotics like trazodone, mirtazapine, tricyclic antidepressants, and hydroxyzine, are used in the treatment of psychiatric disorders and other conditions such as depression, anxiety, psychosis, and insomnia.[143] [144] [145] Ketanserin, a dual serotonin 5-HT2A receptor antagonist and α1-adrenergic receptor antagonist, is used as an antihypertensive agent.[146] The non-selective serotonin 5-HT2A receptor antagonist cyproheptadine is frequently used off-label to treat serotonin syndrome, albeit based on limited clinical evidence.[147] [148] [149] Serotonin 5-HT2A receptor antagonists like ketanserin have been used as psychedelic antidotes or "trip killers" to manage the hallucinogenic effects of serotonergic psychedelics.[150] [151] [152]

List of antagonists

Peripherally selective antagonists

Antagonists and cardiovascular disease

Increased 5-HT2A expression is observed in patients with coronary thrombosis, and the receptor has been associated with processes that influence atherosclerosis.[164] As the receptor is present in coronary arteries[165] and capable of mediating vasoconstriction, 5-HT2A has also been linked to coronary artery spasms.[166] 5-HT antagonism, therefore, has potential in the prevention of cardiovascular disease, however, no studies have been published so far.

Inverse agonists

Positive allosteric modulators

Positive allosteric modulators of the serotonin 5-HT2A receptor have been identified.[175] [176] These include CTW0404 and CTW0419. They selectively potentiated the serotonin 5-HT2A receptor without affecting the serotonin 5-HT2B and 5-HT2C receptors. Unlike serotonin 5-HT2A receptor agonists, they did not substitute for the serotonergic psychedelic (R)-DOI in drug discrimination tests and did not produce the head-twitch response, suggesting that they lack psychedelic effects. Instead, they blunted the (R)-DOI-induced head-twitch response. The (R)-enantiomer of glaucine has also been reported to be a serotonin 5-HT2A receptor positive allosteric modulator.[177] A dual serotonin 5-HT2C and 5-HT2A receptor positive allosteric modulator is the oleamide analogue JPC0323.[178] [179] Another selective serotonin 5-HT2A receptor positive allosteric modulator is AB0124.[180] [181]

Notes and References

  1. Cook EH, Fletcher KE, Wainwright M, Marks N, Yan SY, Leventhal BL . Primary structure of the human platelet serotonin 5-HT2A receptor: identify with frontal cortex serotonin 5-HT2A receptor . Journal of Neurochemistry . 63 . 2 . 465–469 . August 1994 . 8035173 . 10.1046/j.1471-4159.1994.63020465.x . 40207336 .
  2. Kling A . 5-HT2A: a serotonin receptor with a possible role in joint diseases . Umeå, Sweden . 2013 . Ph.D. . Umeå Universitet . 978-91-7459-549-9 .
  3. Book: Raote I . Serotonin 2A (5-HT2A) Receptor Function: Ligand-Dependent Mechanisms and Pathways . Ishier . 2007 . 21204452 . Frontiers in Neuroscience . Press/Taylor & Francis . 978-0-8493-3977-6 .
  4. Gaddum JH, Picarelli ZP . Two kinds of tryptamine receptor . Br J Pharmacol Chemother . 12 . 3 . 323–328 . September 1957 . 13460238 . 1509685 . 10.1111/j.1476-5381.1957.tb00142.x .
  5. Book: Sanders-Bush E, Mayer SE . Brunton LL, Lazo JS, Parker K . Chapter 11: 5-Hydroxytryptamine (Serotonin): Receptor Agonists and Antagonists . Goodman & Gilman's the Pharmacological Basis of Therapeutics . New York . 2006 . 11th . McGraw-Hill . 0-07-142280-3 .
  6. Book: Siegel GJ, Albers RW . Basic neurochemistry: molecular, cellular, and medical aspects . 1 . 241 . 2005 . 7th . 0-12-088397-X . Academic Press .
  7. Hoyer D, Hannon JP, Martin GR . Molecular, pharmacological and functional diversity of 5-HT receptors . Pharmacology, Biochemistry, and Behavior . 71 . 4 . 533–554 . April 2002 . 11888546 . 10.1016/S0091-3057(01)00746-8 . 25543069 .
  8. Chiu YT, Deutch AY, Wang W, Schmitz GP, Huang KL, Kocak DD, Llorach P, Bowyer K, Liu B, Sciaky N, Hua K, Chen C, Mott SE, Niehaus J, DiBerto JF, English J, Walsh JJ, Scherrer G, Herman MA, Wu Z, Wetsel WC, Roth BL . A suite of engineered mice for interrogating psychedelic drug actions . September 2023 . 10.1101/2023.09.25.559347 . The HTR2A was first identified by radioligand binding in 1978 (Leysen et al., 1978), was characterized as a membrane protein in 1985 (Wouters et al., 1985), and its encoding gene, Htr2a, was cloned in 1988 (Pritchett et al., 1988). The structure of Htr2a was characterized further by the Chen and Shih groups for human HTR2A and Toth group for murine Htr2a, who identified various introns, exons, and promoters (Chen et al., 1992; Shih et al., 1996; Toth, 1996)..
  9. Leysen JE, Niemegeers CJ, Tollenaere JP, Laduron PM . Serotonergic component of neuroleptic receptors . Nature . 272 . 5649 . 168–171 . March 1978 . 564466 . 10.1038/272168a0 . 1978Natur.272..168L .
  10. Nichols DE, Nichols CD . Serotonin receptors . Chem Rev . 108 . 5 . 1614–1641 . May 2008 . 18476671 . 10.1021/cr078224o .
  11. Peroutka SJ, Snyder SH . Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol . Mol Pharmacol . 16 . 3 . 687–699 . November 1979 . 530254 . 10.1016/S0026-895X(25)13812-1 .
  12. Wouters W, Van Dun J, Leysen JE, Laduron PM . Solubilization of rat brain serotonin-S2 receptors using CHAPS/salt . Eur J Pharmacol . 115 . 1 . 1–9 . September 1985 . 2931292 . 10.1016/0014-2999(85)90577-1 .
  13. Pritchett DB, Bach AW, Wozny M, Taleb O, Dal Toso R, Shih JC, Seeburg PH . Structure and functional expression of cloned rat serotonin 5HT-2 receptor . EMBO J . 7 . 13 . 4135–4140 . December 1988 . 2854054 . 455123 . 10.1002/j.1460-2075.1988.tb03308.x .
  14. Branchek T, Adham N, Macchi M, Kao HT, Hartig PR . [3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor . Mol Pharmacol . 38 . 5 . 604–609 . November 1990 . 2233697 . 10.1016/S0026-895X(25)09519-7.
  15. Bonis J, Furlong LI, Sanz F . OSIRIS: a tool for retrieving literature about sequence variants . Bioinformatics . 22 . 20 . 2567–2569 . October 2006 . 16882651 . 10.1093/bioinformatics/btl421 . Supplementary material to article . free .
  16. Book: Goldstein AT, Pukall C, Goldstein IL . Fibromyalgia and Female Sexual Pain Disorders . Female Sexual Pain Disorders: Evaluation and Management . 2020 . Wiley . 978-1-119-48266-6 . 2 .
  17. Ruble CL, Smith RM, Calley J, Munsie L, Airey DC, Gao Y, Shin JH, Hyde TM, Straub RE, Weinberger DR, Nisenbaum LK . Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons . BMC Genetics . 17 . 1 . 16 . January 2016 . 26738766 . 4702415 . 10.1186/s12863-015-0325-6 . free .
  18. Medrihan L, Sagi Y, Inde Z, Krupa O, Daniels C, Peyrache A, Greengard P . Initiation of Behavioral Response to Antidepressants by Cholecystokinin Neurons of the Dentate Gyrus . Neuron . 95 . 3 . 564–576.e4 . August 2017 . 28735749 . 10.1016/j.neuron.2017.06.044 . free .
  19. Griffin A, Hamling KR, Knupp K, Hong S, Lee LP, Baraban SC . Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome . Brain . 140 . 3 . 669–683 . March 2017 . 28073790 . 6075536 . 10.1093/brain/aww342 .
  20. Giulietti M, Vivenzio V, Piva F, Principato G, Bellantuono C, Nardi B . How much do we know about the coupling of G-proteins to serotonin receptors? . Molecular Brain . 7 . 1 . 49 . July 2014 . 25011628 . 4105882 . 10.1186/s13041-014-0049-y . free .
  21. Lal D, May P, Perez-Palma E, Samocha KE, Kosmicki JA, Robinson EB, Møller RS, Krause R, Nürnberg P, Weckhuysen S, De Jonghe P, Guerrini R, Niestroj LM, Du J, Marini C, Ware JS, Kurki M, Gormley P, Tang S, Wu S, Biskup S, Poduri A, Neubauer BA, Koeleman BP, Helbig KL, Weber YG, Helbig I, Majithia AR, Palotie A, Daly MJ . Gene family information facilitates variant interpretation and identification of disease-associated genes in neurodevelopmental disorders . Genome Medicine . 12 . 1 . 28 . March 2020 . 32183904 . 7079346 . 10.1186/s13073-020-00725-6 . free .
  22. Gao W, Guo N, Zhao S, Chen Z, Zhang W, Yan F, Liao H, Chi K . HTR2A promotes the development of cardiac hypertrophy by activating PI3K-PDK1-AKT-mTOR signaling . Cell Stress & Chaperones . 25 . 6 . 899–908 . November 2020 . 32519137 . 7591670 . 10.1007/s12192-020-01124-x .
  23. Cao X, Wang Y, Shu D, Qu H, Luo C, Hu X . Food intake-related genes in chicken determined through combinatorial genome-wide association study and transcriptome analysis . Animal Genetics . 51 . 5 . 741–751 . October 2020 . 32720725 . 10.1111/age.12980 . 220839883 .
  24. Garza-Brenner E, Sifuentes-Rincón AM, Randel RD, Paredes-Sánchez FA, Parra-Bracamonte GM, Arellano Vera W, Rodríguez Almeida FA, Segura Cabrera A . Association of SNPs in dopamine and serotonin pathway genes and their interacting genes with temperament traits in Charolais cows . Journal of Applied Genetics . 58 . 3 . 363–371 . August 2017 . 27987181 . 10.1007/s13353-016-0383-0 . 34463383 .
  25. Cheah SY, Lawford BR, Young RM, Morris CP, Voisey J . mRNA Expression and DNA Methylation Analysis of Serotonin Receptor 2A (HTR2A) in the Human Schizophrenic Brain . Genes . 8 . 1 . 14 . January 2017 . 28054990 . 5295009 . 10.3390/genes8010014 . free .
  26. Falkenberg VR, Gurbaxani BM, Unger ER, Rajeevan MS . Functional genomics of serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease association . Neuromolecular Medicine . 13 . 1 . 66–76 . March 2011 . 20941551 . 3044825 . 10.1007/s12017-010-8138-2 .
  27. Kelemen O, Convertini P, Zhang Z, Wen Y, Shen M, Falaleeva M, Stamm S . Function of alternative splicing . Gene . 514 . 1 . 1–30 . February 2013 . 22909801 . 5632952 . 10.1016/j.gene.2012.07.083 .
  28. Wang ET, Ward AJ, Cherone JM, Giudice J, Wang TT, Treacy DJ, Lambert NJ, Freese P, Saxena T, Cooper TA, Burge CB . Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins . Genome Research . 25 . 6 . 858–871 . June 2015 . 25883322 . 4448682 . 10.1101/gr.184390.114 .
  29. Beliveau V, Ganz M, Feng L, Ozenne B, Højgaard L, Fisher PM, Svarer C, Greve DN, Knudsen GM . A High-Resolution In Vivo Atlas of the Human Brain's Serotonin System . The Journal of Neuroscience . 37 . 1 . 120–128 . January 2017 . 28053035 . 5214625 . 10.1523/JNEUROSCI.2830-16.2016 .
  30. Aghajanian GK, Marek GJ . Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release . Brain Research . 825 . 1–2 . 161–171 . April 1999 . 10216183 . 10.1016/S0006-8993(99)01224-X . 20081913 . free .
  31. Marek GJ, Wright RA, Gewirtz JC, Schoepp DD . A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex . Neuroscience . 105 . 2 . 379–392 . 2001 . 11672605 . 10.1016/S0306-4522(01)00199-3 . 19764312 .
  32. Bortolozzi A, Díaz-Mataix L, Scorza MC, Celada P, Artigas F . The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity . Journal of Neurochemistry . 95 . 6 . 1597–1607 . December 2005 . 16277612 . 10.1111/j.1471-4159.2005.03485.x . free . 18350703 . 10261/33026 .
  33. Amargós-Bosch M, Bortolozzi A, Puig MV, Serrats J, Adell A, Celada P, Toth M, Mengod G, Artigas F . Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex . Cerebral Cortex . 14 . 3 . 281–299 . March 2004 . 14754868 . 10.1093/cercor/bhg128 . free . 10261/34683 . free .
  34. Feng J, Cai X, Zhao J, Yan Z . Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons . The Journal of Neuroscience . 21 . 17 . 6502–6511 . September 2001 . 11517239 . 6763081 . 10.1523/JNEUROSCI.21-17-06502.2001 .
  35. Marek GJ . Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats . Neuropharmacology . 56 . 8 . 1082–1087 . June 2009 . 19324062 . 2706691 . 10.1016/j.neuropharm.2009.03.005 .
  36. Zhang C, Marek GJ . AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes . Progress in Neuro-Psychopharmacology & Biological Psychiatry . 32 . 1 . 62–71 . January 2008 . 17728034 . 10.1016/j.pnpbp.2007.07.009 . 44889209 .
  37. Gewirtz JC, Marek GJ . Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors . Neuropsychopharmacology . 23 . 5 . 569–576 . November 2000 . 11027922 . 10.1016/S0893-133X(00)00136-6 . free .
  38. Marek GJ, Zhang C . Activation of metabotropic glutamate 5 (mGlu5) receptors induces spontaneous excitatory synaptic currents in layer V pyramidal cells of the rat prefrontal cortex . Neuroscience Letters . 442 . 3 . 239–243 . September 2008 . 18621097 . 2677702 . 10.1016/j.neulet.2008.06.083 .
  39. Lambe EK, Liu RJ, Aghajanian GK . Schizophrenia, hypocretin (orexin), and the thalamocortical activating system . Schizophrenia Bulletin . 33 . 6 . 1284–1290 . November 2007 . 17656637 . 2779889 . 10.1093/schbul/sbm088 .
  40. Liu RJ, Aghajanian GK . Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy . Proceedings of the National Academy of Sciences of the United States of America . 105 . 1 . 359–364 . January 2008 . 18172209 . 2224217 . 10.1073/pnas.0706679105 . free . 2008PNAS..105..359L .
  41. Geurts FJ, De Schutter E, Timmermans JP . Localization of 5-HT2A, 5-HT3, 5-HT5A and 5-HT7 receptor-like immunoreactivity in the rat cerebellum . Journal of Chemical Neuroanatomy . 24 . 1 . 65–74 . June 2002 . 12084412 . 10.1016/S0891-0618(02)00020-0 . 16510169 .
  42. Maeshima T, Shutoh F, Hamada S, Senzaki K, Hamaguchi-Hamada K, Ito R, Okado N . Serotonin2A receptor-like immunoreactivity in rat cerebellar Purkinje cells . Neuroscience Letters . 252 . 1 . 72–74 . August 1998 . 9756362 . 10.1016/S0304-3940(98)00546-1 . 28549709 .
  43. Maeshima T, Shiga T, Ito R, Okado N . Expression of serotonin2A receptors in Purkinje cells of the developing rat cerebellum . Neuroscience Research . 50 . 4 . 411–417 . December 2004 . 15567478 . 10.1016/j.neures.2004.08.010 . 5772490 .
  44. Dürk T, Panther E, Müller T, Sorichter S, Ferrari D, Pizzirani C, Di Virgilio F, Myrtek D, Norgauer J, Idzko M . 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes . International Immunology . 17 . 5 . 599–606 . May 2005 . 15802305 . 10.1093/intimm/dxh242 . free .
  45. Johansen A, Holm S, Dall B, Keller S, Kristensen JL, Knudsen GM, Hansen HD . Human biodistribution and radiation dosimetry of the 5-HT2A receptor agonist Cimbi-36 labeled with carbon-11 in two positions . EJNMMI Research . 9 . 1 . 71 . July 2019 . 31367837 . 6669221 . 10.1186/s13550-019-0527-4 . free .
  46. Chalit JE, Ragan EJ . The Serotonin G-Protein Coupled Receptor 5HT2A: Molecular and Multiple Sequence Analysis. .
  47. Kimura KT, Asada H, Inoue A, Kadji FM, Im D, Mori C, Arakawa T, Hirata K, Nomura Y, Nomura N, Aoki J, Iwata S, Shimamura T . Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine . Nature Structural & Molecular Biology . 26 . 2 . 121–128 . February 2019 . 30723326 . 10.1038/s41594-018-0180-z .
  48. Viohl N, Hakami Zanjani AA, Khandelia H . Molecular insights into the modulation of the 5HT2A receptor by serotonin, psilocin, and the G protein subunit Gqα . FEBS Letters . 599 . 6 . 876–891 . March 2025 . 39865564 . 11931985 . 10.1002/1873-3468.15099 .
  49. Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD . Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential . Nature Communications . 14 . 1 . 8221 . December 2023 . 38102107 . 10724237 . 10.1038/s41467-023-44016-1 .
  50. Shan J, Khelashvili G, Mondal S, Mehler EL, Weinstein H . Ligand-dependent conformations and dynamics of the serotonin 5-HT(2A) receptor determine its activation and membrane-driven oligomerization properties . PLOS Computational Biology . 8 . 4 . e1002473 . 2012 . 22532793 . 3330085 . 10.1371/journal.pcbi.1002473 . free . 2012PLSCB...8E2473S .
  51. Gumpper RH, Jain MK, Kim K, Sun R, Sun N, Xu Z, DiBerto JF, Krumm BE, Kapolka NJ, Kaniskan HÜ, Nichols DE, Jin J, Fay JF, Roth BL . The structural diversity of psychedelic drug actions revealed . Nature Communications . 16 . 1 . 2734 . March 2025 . 40108183 . 11923220 . 10.1038/s41467-025-57956-7 . 2025NatCo..16.2734G .
  52. Gumpper RH, DiBerto J, Jain M, Kim K, Fay J, Roth BL . Structures of Hallucinogenic and Non-Hallucinogenic Analogues of the 5-HT2A Receptor Reveals Molecular Insights into Signaling Bias . September 2022 . University of North Carolina at Chapel Hill Department of Pharmacology Research Retreat September 16th, 2022 – William and Ida Friday Center . Recently, there has been a resurgence in utilizing classical psychedelics to treat depression, addiction, anxiety disorders, and cluster headaches. The biological target of these compounds, and the route of its therapeutic actions, is the 5HT2A receptor (5HT2AR). It has been hypothesized that the hallucinations and therapeutic actions can be separated through biased agonism and G-protein activation. Here we present 8 new cryoEM structures covering all major compound classes for the 5HT2AR including a novel arrestin biased compound RS130-180. Utilizing the structural and functional data we noticed a correlation between ligand bias and the placement of the canonical "toggle-switch" tryptophan. These findings lead to a broader mechanistic understanding of 5HT2AR activation as well as potential for the development of biased ligands. .
  53. Zhang G, Stackman RW . The role of serotonin 5-HT2A receptors in memory and cognition . Frontiers in Pharmacology . 6 . 225 . 2015 . 26500553 . 4594018 . 10.3389/fphar.2015.00225 . free .
  54. Book: Raote I, Bhattacharya A, Panicker MM . Chattopadhyay A . Serotonin 2A (5-HT2A) Receptor Function: Ligand-Dependent Mechanisms and Pathways. . Serotonin Receptors in Neurobiology. . Frontiers in Neuroscience . Boca Raton (FL) . 2007 . CRC Press/Taylor & Francis . 21204452 . 978-0-8493-3977-6 . https://www.ncbi.nlm.nih.gov/books/NBK1853/ .
  55. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB . Functional selectivity and classical concepts of quantitative pharmacology . The Journal of Pharmacology and Experimental Therapeutics . 320 . 1 . 1–13 . January 2007 . 16803859 . 10.1124/jpet.106.104463 . 447937 .
  56. Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J . Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists . Neuroscience Letters . 493 . 3 . 76–79 . April 2011 . 21276828 . 3064746 . 10.1016/j.neulet.2011.01.046 .
  57. Jalal B . The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug . Psychopharmacology . 235 . 11 . 3083–3091 . November 2018 . 30288594 . 6208952 . 10.1007/s00213-018-5042-1 .
  58. Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD . Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency . The Journal of Pharmacology and Experimental Therapeutics . 327 . 2 . 316–323 . November 2008 . 18708586 . 10.1124/jpet.108.143461 . 25374241 .
  59. Nau F, Yu B, Martin D, Nichols CD . Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo . PLOS ONE . 8 . 10 . e75426 . 2013 . 24098382 . 3788795 . 10.1371/journal.pone.0075426 . free . 2013PLoSO...875426N .
  60. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS . 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells . The Journal of Neuroscience . 21 . 10 . 3572–3579 . May 2001 . 11331386 . 6762485 . 10.1523/JNEUROSCI.21-10-03572.2001 .
  61. Zhang Y, Damjanoska KJ, Carrasco GA, Dudas B, D'Souza DN, Tetzlaff J, Garcia F, Hanley NR, Scripathirathan K, Petersen BR, Gray TS, Battaglia G, Muma NA, Van de Kar LD . Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (−)DOI . The Journal of Neuroscience . 22 . 21 . 9635–9642 . November 2002 . 12417689 . 6758011 . 10.1523/JNEUROSCI.22-21-09635.2002 .
  62. Harvey JA . Role of the serotonin 5-HT(2A) receptor in learning . Learning & Memory . 10 . 5 . 355–362 . 2003 . 14557608 . 218001 . 10.1101/lm.60803 .
  63. Williams GV, Rao SG, Goldman-Rakic PS, Foresta M, Ropolo M, Degan P, Pettinati I, Kow YW, Damonte G, Poggi A, Frosina G . Defective repair of 5-hydroxy-2'-deoxycytidine in Cockayne syndrome cells and its complementation by Escherichia coli formamidopyrimidine DNA glycosylase and endonuclease III . Free Radical Biology & Medicine . 48 . 5 . 681–690 . March 2010 . 11923449 . 20026203-->,10.1016/j.freeradbiomed.2009.12.007 . 6758292 .
  64. Passier A, van Puijenbroek E . Mirtazapine-induced arthralgia . British Journal of Clinical Pharmacology . 60 . 5 . 570–572 . November 2005 . 16236049 . 1884949 . 10.1111/j.1365-2125.2005.02481.x .
  65. Adwan MH . An update on drug-induced arthritis . Rheumatology International . 36 . 8 . 1089–1097 . August 2016 . 27000044 . 10.1007/s00296-016-3462-y . 25401280 .
  66. Herth MM, Knudsen GM . Current radiosynthesis strategies for 5-HT2A receptor PET tracers . Journal of Labelled Compounds & Radiopharmaceuticals . 58 . 7 . 265–273 . June 2015 . 25997728 . 10.1002/jlcr.3288 .
  67. Web site: Beer R . Anblick von toten Fliegen lässt Fliegen altern . 2023-06-13 . 2023-06-14 . science.ORF.at . de .
  68. Gendron CM, Chakraborty TS, Duran C, Dono T, Pletcher SD . Ring neurons in the Drosophila central complex act as a rheostat for sensory modulation of aging . PLOS Biology . 21 . 6 . e3002149 . June 2023 . 37310911 . 10263353 . 10.1371/journal.pbio.3002149 . free .
  69. Nichols DE . Hallucinogens . Pharmacology & Therapeutics . 101 . 2 . 131–181 . February 2004 . 14761703 . 10.1016/j.pharmthera.2003.11.002 .
  70. Blaazer AR, Smid P, Kruse CG . Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors . ChemMedChem . 3 . 9 . 1299–1309 . September 2008 . 18666267 . 10.1002/cmdc.200800133 . 7537908 .
  71. Moreno JL, Muguruza C, Umali A, Mortillo S, Holloway T, Pilar-Cuéllar F, Mocci G, Seto J, Callado LF, Neve RL, Milligan G, Sealfon SC, López-Giménez JF, Meana JJ, Benson DL, González-Maeso J . Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function . The Journal of Biological Chemistry . 287 . 53 . 44301–44319 . December 2012 . 23129762 . 3531745 . 10.1074/jbc.M112.413161 . free .
  72. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC . Identification of a serotonin/glutamate receptor complex implicated in psychosis . Nature . 452 . 7183 . 93–97 . March 2008 . 18297054 . 2743172 . 10.1038/nature06612 . 2008Natur.452...93G .
  73. Taddeucci A, Olivero G, Roggeri A, Milanese C, Giorgio FP, Grilli M, Marchi M, Garrone B, Pittaluga A . Presynaptic 5-HT2A-mGlu2/3 Receptor-Receptor Crosstalk in the Prefrontal Cortex: Metamodulation of Glutamate Exocytosis . Cells . 11 . 19 . 3035 . September 2022 . 36230998 . 9562019 . 10.3390/cells11193035 . free .
  74. Wingen M, Kuypers KP, Ramaekers JG . The role of 5-HT1a and 5-HT2A receptors in attention and motor control: a mechanistic study in healthy volunteers . Psychopharmacology . 190 . 3 . 391–400 . February 2007 . 17124621 . 10.1007/s00213-006-0614-x . 25125461 .
  75. Wingen M, Kuypers KP, Ramaekers JG . Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI . Journal of Psychopharmacology . 21 . 5 . 477–485 . July 2007 . 17092965 . 10.1177/0269881106072506 . 19575488 .
  76. Nichols DE . Psychedelics . Pharmacol Rev . 68 . 2 . 264–355 . April 2016 . 26841800 . 4813425 . 10.1124/pr.115.011478 .
  77. Duan W, Cao D, Wang S, Cheng J . Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants . Chem Rev . 124 . 1 . 124–163 . January 2024 . 38033123 . 10.1021/acs.chemrev.3c00375 .
  78. Atiq MA, Baker MR, Voort JL, Vargas MV, Choi DS . Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties . Psychopharmacology (Berl) . May 2024 . 242 . 7 . 1481–1506 . 38743110 . 10.1007/s00213-024-06599-5 . free . 12226698 .
  79. Hinkle JT, Graziosi M, Nayak SM, Yaden DB . Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis . JAMA Psychiatry . 81 . 12 . 1225–1235 . December 2024 . 39230883 . 11375525 . 10.1001/jamapsychiatry.2024.2546 .
  80. Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ . Adverse effects of psychedelics: From anecdotes and misinformation to systematic science . J Psychopharmacol . 36 . 3 . 258–272 . March 2022 . 35107059 . 8905125 . 10.1177/02698811211069100 .
  81. Roth BL, Gumpper RH . Psychedelics as Transformative Therapeutics . Am J Psychiatry . 180 . 5 . 340–347 . May 2023 . 37122272 . 10.1176/appi.ajp.20230172 .
  82. Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST . Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders . Drug Discov Today . 28 . 12 . 103818 . December 2023 . 37925136 . 10.1016/j.drudis.2023.103818 .
  83. Nutt D, Spriggs M, Erritzoe D . Psychedelics therapeutics: What we know, what we think, and what we need to research . Neuropharmacology . 223 . 109257 . February 2023 . 36179919 . 10.1016/j.neuropharm.2022.109257 . free .
  84. Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE . Psychedelics and Other Psychoplastogens for Treating Mental Illness . Front Psychiatry . 12 . 727117 . 2021 . 34671279 . 8520991 . 10.3389/fpsyt.2021.727117 . free .
  85. Aday JS, Barnett BS, Grossman D, Murnane KS, Nichols CD, Hendricks PS . Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry . Psychedelic Medicine . 1 . 3 . 150–165 . September 2023 . 40046566 . 11661494 . 10.1089/psymed.2023.0013 .
  86. Hatzipantelis CJ, Olson DE . The Effects of Psychedelics on Neuronal Physiology . Annu Rev Physiol . 86 . 27–47 . February 2024 . 37931171 . 10922499 . 10.1146/annurev-physiol-042022-020923 .
  87. Olson DE . Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity . Biochemistry . 61 . 3 . 127–136 . February 2022 . 35060714 . 9004607 . 10.1021/acs.biochem.1c00812 .
  88. Nichols DE, Johnson MW, Nichols CD . Psychedelics as Medicines: An Emerging New Paradigm . Clin Pharmacol Ther . 101 . 2 . 209–219 . February 2017 . 28019026 . 10.1002/cpt.557 .
  89. Book: Flanagan TW, Nichols CD . Psychedelics and Anti-inflammatory Activity in Animal Models . Disruptive Psychopharmacology . 56 . 229–245 . 2022 . 35546383 . 10.1007/7854_2022_367 . Current Topics in Behavioral Neurosciences . 978-3-031-12183-8 .
  90. Nichols CD . Psychedelics as potent anti-inflammatory therapeutics . Neuropharmacology . 219 . 109232 . November 2022 . 36007854 . 10.1016/j.neuropharm.2022.109232 . free .
  91. Flanagan TW, Nichols CD . Psychedelics as anti-inflammatory agents . Int Rev Psychiatry . 30 . 4 . 363–375 . August 2018 . 30102081 . 10.1080/09540261.2018.1481827 .
  92. Thompson C, Szabo A . Psychedelics as a novel approach to treating autoimmune conditions . Immunol Lett . 228 . 45–54 . December 2020 . 33035575 . 10.1016/j.imlet.2020.10.001 . 10852/80687 . free .
  93. Low ZX, Ng WS, Lim ES, Goh BH, Kumari Y . The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies . Prog Neuropsychopharmacol Biol Psychiatry . 136 . 111139 . September 2024 . 39251080 . 10.1016/j.pnpbp.2024.111139 . free .
  94. Flanagan TW, Billac GB, Landry AN, Sebastian MN, Cormier SA, Nichols CD . Structure-Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore . ACS Pharmacol Transl Sci . 4 . 2 . 488–502 . April 2021 . 33860179 . 8033619 . 10.1021/acsptsci.0c00063 .
  95. Flanagan TW, Billac G, Nichols CD . Differential Regulation of Inflammatory Responses Following 5-HT 2 Receptor Activation in Pulmonary Tissues . The FASEB Journal . 36 . S1 . 2022 . fasebj.2022.36.S1.R2617 . 10.1096/fasebj.2022.36.S1.R2617 . 0892-6638 . free .
  96. Flanagan TW, Foster TP, Galbato TE, Lum PY, Louie B, Song G, Halberstadt AL, Billac GB, Nichols CD . Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 Expression . ACS Pharmacology & Translational Science . 7 . 2 . 478–492 . February 2024 . 38357283 . 10863441 . 10.1021/acsptsci.3c00297 . The effects of (R)-DOTFM were examined in the head-twitch response (HTR) assay. (R)-DOTFM produced a strong HTR with a potent ED 50 of 0.60 μmol/kg. These values are equivalent to (R)-DOI, as previously determined. .
  97. Web site: Eleusis Draws on Research Into Psychedelics To Develop New Medicines for Inflammation . 8 July 2020 . Newvine C . Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness . 16 February 2025 .
  98. Eleusis Drug Development Overview . February 2020 . Shlomi Raz, Eleusis . LSX World Congress 2020 .
  99. Compounds and methods for treating inflammatory disorders . WO . 2020210823 . . Gerald Billac . . published . 15 October 2020 . 13 April 2020 . 13 April 2020 .
  100. Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D . Microdosing psychedelics: More questions than answers? An overview and suggestions for future research . J Psychopharmacol . 33 . 9 . 1039–1057 . September 2019 . 31303095 . 6732823 . 10.1177/0269881119857204 .
  101. Kinderlehrer DA . Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity . Neuropsychiatr Dis Treat . 21 . 141–155 . 2025 . 39897712 . 11787777 . 10.2147/NDT.S500337 . free .
  102. Kozlowska U, Nichols C, Wiatr K, Figiel M . From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders . J Neurochem . 162 . 1 . 89–108 . July 2022 . 34519052 . 10.1111/jnc.15509 .
  103. Family N, Maillet EL, Williams LT, Krediet E, Carhart-Harris RL, Williams TM, Nichols CD, Goble DJ, Raz S . Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers . Psychopharmacology (Berl) . 237 . 3 . 841–853 . March 2020 . 31853557 . 7036065 . 10.1007/s00213-019-05417-7 .
  104. Ettrup A, da Cunha-Bang S, McMahon B, Lehel S, Dyssegaard A, Skibsted AW, Jørgensen LM, Hansen M, Baandrup AO, Bache S, Svarer C, Kristensen JL, Gillings N, Madsen J, Knudsen GM . Serotonin 2A receptor agonist binding in the human brain with [¹¹C]Cimbi-36 . Journal of Cerebral Blood Flow and Metabolism . 34 . 7 . 1188–1196 . July 2014 . 24780897 . 4083382 . 10.1038/jcbfm.2014.68 .
  105. Braden MR, Parrish JC, Naylor JC, Nichols DE . Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists . Molecular Pharmacology . 70 . 6 . 1956–1964 . December 2006 . 17000863 . 10.1124/mol.106.028720 . 15840304 .
  106. Prabhakaran J, Solingapuram Sai KK, Zanderigo F, Rubin-Falcone H, Jorgensen MJ, Kaplan JR, Tooke KI, Mintz A, Mann JJ, Kumar JS . In vivo evaluation of [<sup>18</sup>F]FECIMBI-36, an agonist 5-HT2A/2C receptor PET radioligand in nonhuman primate . Bioorganic & Medicinal Chemistry Letters . 27 . 1 . 21–23 . January 2017 . 27889455 . 5348621 . 10.1016/j.bmcl.2016.11.043 .
  107. Ennis MD, Hoffman RL, Ghazal NB, Olson RM, Knauer CS, Chio CL, Hyslop DK, Campbell JE, Fitzgerald LW, Nichols NF, Svensson KA, McCall RB, Haber CL, Kagey ML, Dinh DM . 2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists . Bioorganic & Medicinal Chemistry Letters . 13 . 14 . 2369–2372 . July 2003 . 12824036 . 10.1016/S0960-894X(03)00403-7 .
  108. McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE . 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists . Journal of Medicinal Chemistry . 49 . 19 . 5794–5803 . September 2006 . 16970404 . 10.1021/jm060656o .
  109. Hansen M . Ph.D. . University of Copenhagen . Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Revised, Duplex print).pdf . Google Docs .
  110. Åstrand A, Guerrieri D, Vikingsson S, Kronstrand R, Green H . In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT1A, and 5-HT2A receptors-On-target receptor potency and efficacy, and off-target effects . Forensic Science International . 317 . 110553 . December 2020 . 33160102 . 10.1016/j.forsciint.2020.110553 . free .
  111. Vasilkevich A, Duan J, Lovera A, McCorvy J, Pedersen JT . Novel 5-HT2A/2C mixed and partial agonist and its efficacy in preclinical pain models . October 2024 . Society for Neuroscience 2024 Annual Meeting, Chicago, October 5–9 .
  112. Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE . Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists . Journal of Medicinal Chemistry . 44 . 6 . 1003–1010 . March 2001 . 11300881 . 10.1021/jm000491y .
  113. Juncosa JI, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, Marona-Lewicka D, Lill MA, Nichols DE . Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands . ACS Chemical Neuroscience . 4 . 1 . 96–109 . January 2013 . 23336049 . 3547484 . 10.1021/cn3000668 .
  114. Canal CE, Morgan D . Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model . Drug Testing and Analysis . 4 . 7–8 . 556–576 . July 2012 . 22517680 . 3722587 . 10.1002/dta.1333 .
  115. Gatch MB, Kozlenkov A, Huang RQ, Yang W, Nguyen JD, González-Maeso J, Rice KC, France CP, Dillon GH, Forster MJ, Schetz JA . The HIV antiretroviral drug efavirenz has LSD-like properties . Neuropsychopharmacology . 38 . 12 . 2373–2384 . November 2013 . 23702798 . 3799056 . 10.1038/npp.2013.135 .
  116. Cao D, Yu J, Wang H, Luo Z, Liu X, He L, Qi J, Fan L, Tang L, Chen Z, Li J, Cheng J, Wang S . Structure-based discovery of nonhallucinogenic psychedelic analogs . Science . 375 . 6579 . 403–411 . January 2022 . 35084960 . 10.1126/science.abl8615 . 246360313 . 2022Sci...375..403C .
  117. Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M . Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors . Psychopharmacology . 136 . 4 . 409–414 . April 1998 . 9600588 . 10.1007/s002130050585 . 3021798 .
  118. Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B . Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis . Clinical Neuropharmacology . 29 . 2 . 80–86 . 2006 . 16614540 . 10.1097/00002826-200603000-00005 . 33849447 .
  119. Janowsky A, Eshleman AJ, Johnson RA, Wolfrum KM, Hinrichs DJ, Yang J, Zabriskie TM, Smilkstein MJ, Riscoe MK . Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro . Psychopharmacology . 231 . 14 . 2771–2783 . July 2014 . 24488404 . 4097020 . 10.1007/s00213-014-3446-0 .
  120. de la Fuente Revenga M, Shah UH, Nassehi N, Jaster AM, Hemanth P, Sierra S, Dukat M, González-Maeso J . Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice . ACS Chemical Neuroscience . 12 . 5 . 831–844 . March 2021 . 33400504 . 7933111 . 10.1021/acschemneuro.0c00291 .
  121. Ennis MD, Hoffman RL, Ghazal NB, Olson RM, Knauer CS, Chio CL, Hyslop DK, Campbell JE, Fitzgerald LW, Nichols NF, Svensson KA, McCall RB, Haber CL, Kagey ML, Dinh DM . 2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists . Bioorganic & Medicinal Chemistry Letters . 13 . 14 . 2369–2372 . July 2003 . 12824036 . 10.1016/s0960-894x(03)00403-7 .
  122. Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, Sengupta D, Thomsen WJ, Saldana HR, Whelan KT, Menzaghi F, Webb RR, Beeley NR . Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity . Bioorganic & Medicinal Chemistry Letters . 15 . 5 . 1467–1470 . March 2005 . 15713408 . 10.1016/j.bmcl.2004.12.080 .
  123. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma . WO . WO2007149728 . Mohapatra S, Hellberg MR, Feng Z . Alcon Manufacturing, Ltd. .
  124. Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, Sengupta D, Dosa PI, Covel JA, Ren A, Webb RR, Beeley NR, Martin M, Morgan M, Espitia S, Saldana HR, Bjenning C, Whelan KT, Grottick AJ, Menzaghi F, Thomsen WJ . Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity . Journal of Medicinal Chemistry . 51 . 2 . 305–313 . January 2008 . 18095642 . 10.1021/jm0709034 .
  125. Jensen AA, Plath N, Pedersen MH, Isberg V, Krall J, Wellendorph P, Stensbøl TB, Gloriam DE, Krogsgaard-Larsen P, Frølund B . Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT(2A)/5-HT(2C) receptor agonists with pro-cognitive properties . Journal of Medicinal Chemistry . 56 . 3 . 1211–1227 . February 2013 . 23301527 . 10.1021/jm301656h .
  126. Orr MJ, Cao AB, Wang CT, Gaisin A, Csakai A, Friswold AP, Meltzer HY, McCorvy JD, Scheidt KA . Discovery of Highly Potent Serotonin 5-HT2 Receptor Agonists Inspired by Heteroyohimbine Natural Products . ACS Medicinal Chemistry Letters . 13 . 4 . 648–657 . April 2022 . 35450369 . 9014500 . 10.1021/acsmedchemlett.1c00694 .
  127. Kaplan AL, Confair DN, Kim K, Barros-Álvarez X, Rodriguiz RM, Yang Y, Kweon OS, Che T, McCorvy JD, Kamber DN, Phelan JP, Martins LC, Pogorelov VM, DiBerto JF, Slocum ST, Huang XP, Kumar JM, Robertson MJ, Panova O, Seven AB, Wetsel AQ, Wetsel WC, Irwin JJ, Skiniotis G, Shoichet BK, Roth BL, Ellman JA . Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity . Nature . 610 . 7932 . 582–591 . October 2022 . 36171289 . 9996387 . 10.1038/s41586-022-05258-z . 2022Natur.610..582K . 252598838 .
  128. Lyu J, Kapolka N, Gumpper R, Alon A, Wang L, Jain MK, Barros-Álvarez X, Sakamoto K, Kim Y, DiBerto J, Kim K, Tummino TA, Huang S, Irwin JJ, Tarkhanova OO, Moroz Y, Skiniotis G, Kruse AC, Shoichet BK, Roth BL . AlphaFold2 structures template ligand discovery . December 2023 . 10.1101/2023.12.20.572662 .
  129. Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, Azinfar A, Oh WC, Wetsel WC, Olson DE, Tian L . Psychedelic-inspired drug discovery using an engineered biosensor . Cell . 184 . 10 . 2779–2792.e18 . May 2021 . 33915107 . 8122087 . 10.1016/j.cell.2021.03.043 . free .
  130. Märcher Rørsted E, Jensen AA, Kristensen JL . 25CN-NBOH: A Selective Agonist for in vitro and in vivo Investigations of the Serotonin 2A Receptor . ChemMedChem . 16 . 21 . 3263–3270 . November 2021 . 34288515 . 10.1002/cmdc.202100395 .
  131. Vasilkevich A, Halberstadt AL, Duan J, Merritt CR, Cunningham KA, McCorvy J, Kozikowski A, Pedersen J . Novel 5-HT2A selective agonists with well-characterized PK profile and short duration of action . October 2024 . Society for Neuroscience 2024 Annual Meeting (Chicago), October 5–9 .
  132. Juncosa JI, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, Marona-Lewicka D, Lill MA, Nichols DE . Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands . ACS Chem Neurosci . 4 . 1 . 96–109 . January 2013 . 23336049 . 3547484 . 10.1021/cn3000668 .
  133. Xu Z, Wang H, Yu J, Deng Y, Tian X, Ni R, Xia F, Yang L, Xu C, Zhang L, Luo R, Chen P, Zhang X, Liu Y, Hou J, Zhang M, Chen S, Su L, Sun H, He Y, Chen D, Chen X, Miao Z, Xie J, Liu X, Zhao J, Ke B, Tian X, Zeng L, Zhang L, Tang X, Yang S, Liu J, Wang X, Yan W, Shao Z . Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling . Nature . January 2026 . 41606342 . 10.1038/s41586-025-10061-7 .
  134. M Ro Rsted E, Jensen AA, Smits G, Frydenvang K, Kristensen JL . Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists . Journal of Medicinal Chemistry . 67 . 9 . 7224–7244 . May 2024 . 38648420 . 11089506 . 10.1021/acs.jmedchem.4c00082 .
  135. Jensen AA, Cecchi CR, Hibicke M, Bach AH, Kaadt E, Marcher-Rorsted E, Nichols CD, Elfving B, Kristensen JL . The selective 5-HT 2A receptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents . 22 April 2024 . 10.1101/2024.04.19.590212 .
  136. Web site: LPH 48 . 22 May 2024 . AdisInsight . 30 October 2024 .
  137. Yuan H, Guo Z, Luo T . Synthesis of (+)-Lysergol and Its Analogues To Assess Serotonin Receptor Activity . Org Lett . 19 . 3 . 624–627 . February 2017 . 28106398 . 10.1021/acs.orglett.6b03779 .
  138. Indole compounds useful as serotonin selective agents. . US . 7655691 . Kumaran G, Morency C, Roth B, Sard HP, Shuster L Xu L . Organix Inc . 11 May 2006 .
  139. Motaghinejad O, Motaghinejad M, Motevalian M, Rahimi-Sharbaf F, Beiranvand T . The effect of maternal forced exercise on offspring pain perception, motor activity and anxiety disorder: the role of 5-HT2 and D2 receptors and CREB gene expression . Journal of Exercise Rehabilitation . 13 . 5 . 514–525 . October 2017 . 29114525 . 5667597 . 10.12965/jer.1734992.496 .
  140. Fenske TG, McKee JL, Cavalco NG, Schalk SS, Bonniwell EM, Lammers JC, Shacham N, Cuccurazzu B, Halberstadt AL, McCorvy JD . Discovery of Highly Selective 5-HT2A Agonists Using Structure-Guided Design . J Med Chem . 68. 19. 20619–20635. September 2025 . 40997862 . 10.1021/acs.jmedchem.5c01855 . 12713736 .
  141. Sharif NA, McLaughlin MA, Kelly CR . AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist . Journal of Ocular Pharmacology and Therapeutics . 23 . 1 . 1–13 . February 2007 . 17341144 . 10.1089/jop.2006.0093 .
  142. May JA, Dantanarayana AP, Zinke PW, McLaughlin MA, Sharif NA . 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity . Journal of Medicinal Chemistry . 49 . 1 . 318–328 . January 2006 . 16392816 . 10.1021/jm050663x .
  143. Mestre TA, Zurowski M, Fox SH . 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders . Expert Opin Investig Drugs . 22 . 4 . 411–421 . April 2013 . 23409724 . 10.1517/13543784.2013.769957 .
  144. de Angelis L . 5-HT2A antagonists in psychiatric disorders . Curr Opin Investig Drugs . 3 . 1 . 106–112 . January 2002 . 12054060 .
  145. Casey AB, Cui M, Booth RG, Canal CE . "Selective" serotonin 5-HT2A receptor antagonists . Biochem Pharmacol . 200 . 115028 . June 2022 . 35381208 . 9252399 . 10.1016/j.bcp.2022.115028 .
  146. Brogden RN, Sorkin EM . Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease . Drugs . 40 . 6 . 903–949 . December 1990 . 2079001 . 10.2165/00003495-199040060-00010 .
  147. Badr B, Naguy A . Cyproheptadine: a psychopharmacological treasure trove? . CNS Spectr . 27 . 5 . 533–535 . October 2022 . 33632345 . 10.1017/S1092852921000250 .
  148. Badar A . Serotonin syndrome: An often-neglected medical emergency . J Family Community Med . 31 . 1 . 1–8 . 2024 . 38406216 . 10883429 . 10.4103/jfcm.jfcm_236_23 . free .
  149. King E, Rotella JA . Review article: Efficacy of cyproheptadine in the management of serotonin toxicity following deliberate self-poisoning - A systematic review . Emerg Med Australas . 37 . 1 . e14554 . February 2025 . 39791184 . 10.1111/1742-6723.14554 .
  150. Halman A, Kong G, Sarris J, Perkins D . Drug-drug interactions involving classic psychedelics: A systematic review . J Psychopharmacol . 38 . 1 . 3–18 . January 2024 . 37982394 . 10851641 . 10.1177/02698811231211219 .
  151. Book: Halberstadt AL, Nichols DE . Serotonin and serotonin receptors in hallucinogen action . Handbook of the Behavioral Neurobiology of Serotonin . 31 . 843–863 . 2020 . 10.1016/B978-0-444-64125-0.00043-8 . Handbook of Behavioral Neuroscience . 1569-7339 . 978-0-444-64125-0 . 241134396 .
  152. Yates G, Melon E . Trip-killers: a concerning practice associated with psychedelic drug use . Emerg Med J . 41 . 2 . 112–113 . January 2024 . 38123961 . 10.1136/emermed-2023-213377 . https://web.archive.org/web/20250511111827/https://s3.amazonaws.com/crawl.prod.proquest.com/fpcache/71f445805bfb61341cbc438c8ae23bd3.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEBMaCXVzLWVhc3QtMSJIMEYCIQDETX7YpaG5THA%2FNbKR0d92wr6h%2Bgg9preNcKjAsEqo%2BQIhAIlPGGWOeUc23LqhBzRYbxvSXB9aqSe2vVonl4nacAhhKp0CCLz%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQABoMNTE4MzQ2ODQ4MzQxIgy9ji58Qtbi%2BavuKeYq8QEDL1U5KZDQ0bXFyVapeqJgE%2FX6x8DcJfFU8DAXYZPSQEwrIdfPbZWcYsH340deru%2FUHnNaGGpuHFoVzui%2FMbqBz7MANcowj%2FL1%2BQZzQ5hXh5KM3BW8E6NRzrQyuPRmBy7kQUkx8%2BjTN%2BXSMgF%2FCAs6Dn9fScgBGz3ddkwRZXDkjasqMP65RCPKhagK68cyMbf3oX%2BKS8a4Kltc2rk3CnWEhOKrZU4mIxq07DikLAXQbl8YRZJIkeOhN5TgBaLWJqyn1td2VWCMymAaFsqtPWHwXnEfsolRlfDooe6QXfE2YwX5PxBVJU7GPXRgrAqPjwtJMOCHgsEGOpwBYif%2BaDMBdz3IEghuvCvorAS0mkHzdcOz%2Fi7AzuN9nch%2FIm8llhMsN41aAWHuSG25pnhhftauFsg7rbGsrW2nl2kq2upi9zP7y%2Fnqk93jcP0kr0jM8zU12bYoSTsToQJsshH4N%2BTQUMwlzRQfeVv8MXdq%2BgSTTzJrWNwT1yNzye3rSHjvOumbNl6sgBISw7QqRzhB6hZTuf8AcI%2B7&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20250511T111826Z&X-Amz-SignedHeaders=host&X-Amz-Credential=ASIAXRL7BHBKRAKCQVVB%2F20250511%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Expires=3600&X-Amz-Signature=20bb1b90e4c8dbaa4115c954387617ebe2f55269bdd517692f1380193ed3f769 . 2025-05-11 .
  153. Shireman BT, Dvorak CA, Rudolph DA, Bonaventure P, Nepomuceno D, Dvorak L, Miller KL, Lovenberg TW, Carruthers NI . 2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists . Bioorganic & Medicinal Chemistry Letters . 18 . 6 . 2103–2108 . March 2008 . 18282705 . 10.1016/j.bmcl.2008.01.090 .
  154. Westkaemper RB, Runyon SP, Bondarev ML, Savage JE, Roth BL, Glennon RA . 9-(Aminomethyl)-9,10-dihydroanthracene is a novel and unlikely 5-HT2A receptor antagonist . European Journal of Pharmacology . 380 . 1 . R5–R7 . September 1999 . 10513561 . 10.1016/S0014-2999(99)00525-7 .
  155. Westkaemper RB, Glennon RA . Application of ligand SAR, receptor modeling and receptor mutagenesis to the discovery and development of a new class of 5-HT(2A) ligands . Current Topics in Medicinal Chemistry . 2 . 6 . 575–598 . June 2002 . 12052195 . 10.2174/1568026023393741 . 23576058 .
  156. Peddi S, Roth BL, Glennon RA, Westkaemper RB . Spiro[9,10-dihydroanthracene]-9,3'-pyrrolidine-a structurally unique tetracyclic 5-HT2A receptor antagonist . European Journal of Pharmacology . 482 . 1–3 . 335–337 . December 2003 . 14660041 . 10.1016/j.ejphar.2003.09.059 .
  157. Runyon SP, Mosier PD, Roth BL, Glennon RA, Westkaemper RB . Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation . Journal of Medicinal Chemistry . 51 . 21 . 6808–6828 . November 2008 . 18847250 . 3088499 . 10.1021/jm800771x .
  158. Wilson KJ, van Niel MB, Cooper L, Bloomfield D, O'Connor D, Fish LR, MacLeod AM . 2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands . Bioorganic & Medicinal Chemistry Letters . 17 . 9 . 2643–2648 . May 2007 . 17314044 . 10.1016/j.bmcl.2007.01.098 .
  159. Ishima T, Futamura T, Ohgi Y, Yoshimi N, Kikuchi T, Hashimoto K . Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors . European Neuropsychopharmacology . 25 . 4 . 505–511 . April 2015 . 25687838 . 10.1016/j.euroneuro.2015.01.014 . free .
  160. Das S, Barnwal P, Winston AB, Mondal S, Saha I . Brexpiprazole: so far so good . Therapeutic Advances in Psychopharmacology . 6 . 1 . 39–54 . February 2016 . 26913177 . 4749739 . 10.1177/2045125315614739 .
  161. Book: Rang HP . Pharmacology . Edinburgh . 2003 . Churchill Livingstone . 0-443-07145-4 . Page 187
  162. Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J . Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor . Psychopharmacology . 126 . 3 . 234–240 . August 1996 . 8876023 . 10.1007/bf02246453 . 24889381 .
  163. Marek GJ, Martin-Ruiz R, Abo A, Artigas F . The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine . Neuropsychopharmacology . 30 . 12 . 2205–2215 . December 2005 . 15886717 . 10.1038/sj.npp.1300762 . free .
  164. Marcinkowska M, Kubacka M, Zagorska A, Jaromin A, Fajkis-Zajaczkowska N, Kolaczkowski M . Exploring the antiplatelet activity of serotonin 5-HT2A receptor antagonists bearing 6-fluorobenzo[d]isoxazol-3-yl)propyl) motif- as potential therapeutic agents in the prevention of cardiovascular diseases . Biomedicine & Pharmacotherapy . 145 . 112424 . January 2022 . 34785417 . 10.1016/j.biopha.2021.112424 . 244111116 . free .
  165. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, Edvinsson L . Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques . European Journal of Pharmacology . 372 . 1 . 49–56 . May 1999 . 10374714 . 10.1016/S0014-2999(99)00114-4 .
  166. Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T . Functions of 5-HT2A receptor and its antagonists in the cardiovascular system . Pharmacology & Therapeutics . 104 . 1 . 59–81 . October 2004 . 15500909 . 10.1016/j.pharmthera.2004.08.005 .
  167. Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR . 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics . The Journal of Pharmacology and Experimental Therapeutics . 299 . 1 . 268–276 . October 2001 . 11561089 . 10.1016/S0022-3565(24)29327-7 .
  168. Vanover KE, Harvey SC, Son T, Bradley SR, Kold H, Makhay M, Veinbergs I, Spalding TA, Weiner DM, Andersson CM, Tolf BR, Brann MR, Hacksell U, Davis RE . Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist . The Journal of Pharmacology and Experimental Therapeutics . 310 . 3 . 943–951 . September 2004 . 15102927 . 10.1124/jpet.104.066688 . 12205122 .
  169. Rosenberg R, Seiden DJ, Hull SG, Erman M, Schwartz H, Anderson C, Prosser W, Shanahan W, Sanchez M, Chuang E, Roth T . APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia . Sleep . 31 . 12 . 1663–1671 . December 2008 . 19090322 . 2603489 . 10.1093/sleep/31.12.1663 .
  170. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE . Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist . The Journal of Pharmacology and Experimental Therapeutics . 317 . 2 . 910–918 . May 2006 . 16469866 . 10.1124/jpet.105.097006 . 22681576 .
  171. Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, Veinbergs I, Dyssegaard A, Brunmark P, Tabatabaei A, Davis RE, Brann MR, Hacksell U, Bonhaus DW . ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models . The Journal of Pharmacology and Experimental Therapeutics . 322 . 2 . 862–870 . August 2007 . 17519387 . 10.1124/jpet.107.121715 . 28861527 .
  172. Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD . A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model . Pharmacology, Biochemistry, and Behavior . 90 . 4 . 540–544 . October 2008 . 18534670 . 2806670 . 10.1016/j.pbb.2008.04.010 .
  173. Abbas A, Roth BL . Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders . Expert Opinion on Pharmacotherapy . 9 . 18 . 3251–3259 . December 2008 . 19040345 . 10.1517/14656560802532707 . 71240383 .
  174. Web site: FDA approves first drug to treat hallucinations and delusions associated with Parkinson's disease . 10 September 2019 . https://web.archive.org/web/20190907164751/https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-hallucinations-and-delusions-associated-parkinsons-disease . 7 September 2019 . Office of the Commissioner . FDA .
  175. Merritt C, Bolinger A, Anastasio N, Zhou J, Cunningham K . ACNP 61st Annual Meeting: Poster Abstracts P541 - P809: P722. Novel Positive Allosteric Modulators Augment 5-HT2A Receptor Functionality . Neuropsychopharmacology . 47 . Suppl 1 . 371–520 (470–470) . December 2022 . 36456695 . 9714408 . 10.1038/s41386-022-01486-z .
  176. Zamora JC, Merritt CR, Bolinger AA, Fox RG, Wild CT, Wold EA, Garcia EJ, Pazdrak K, Mifflin RC, Stafford SJ, Anastasio NC . Serendipitous Discovery of Novel 5-HT2AR Positive Allosteric Modulators (PAMs) Derived From 5-HT2CR PAM Scaffolds . The Journal of Pharmacology and Experimental Therapeutics . 389 . 2024 . 10.1124/jpet.087.985400 . 87 .
  177. Heng HL, Chee CF, Thy CK, Tee JT, Chin SP, Herr DR, Buckle MJ, Paterson IC, Doughty SW, Abd Rahman N, Chung LY . In vitro functional evaluation of isolaureline, dicentrine and glaucine enantiomers at 5-HT2 and α1 receptors . Chem Biol Drug Des . 93 . 2 . 132–138 . February 2019 . 30216681 . 10.1111/cbdd.13390 .
  178. Brunetti L, Francavilla F, Leopoldo M, Lacivita E . Allosteric Modulators of Serotonin Receptors: A Medicinal Chemistry Survey . Pharmaceuticals (Basel) . 17 . 6 . May 2024 . 695 . 38931362 . 11206742 . 10.3390/ph17060695 . free . Several compounds of this series showed significant efficacy at 1 nM in improving 5-HT-mediated calcium efflux. Interestingly, while some of them were selective PAMs of 5-HT2CR, others were described as dual 5-HT2AR/5-HT2CR PAMs. None of these compounds were reported as PAMs of 5-HT2BR. A full characterization was conducted for dual PAM JPC0323 (Figure 6), which evoked a 44% increase in maximum 5-HT-induced Ca2+ intake and also showed negligible displacement at orthosteric binding sites of a number of GPCRs and transporters and exhibited favorable pharmacokinetic parameters. In rats, JPC0323 suppressed spontaneous ambulation in a 5-HT2CR-dependent manner, suggesting that the compound has a preference for 5-HT2CR over 5-HT2AR [75]..
  179. Chen J, Garcia EJ, Merritt CR, Zamora JC, Bolinger AA, Pazdrak K, Stafford SJ, Mifflin RC, Wold EA, Wild CT, Chen H, Anastasio NC, Cunningham KA, Zhou J . Discovery of Novel Oleamide Analogues as Brain-Penetrant Positive Allosteric Serotonin 5-HT2C Receptor and Dual 5-HT2C/5-HT2A Receptor Modulators . J Med Chem . 66 . 14 . 9992–10009 . July 2023 . 37462530 . 10853020 . 10.1021/acs.jmedchem.3c00908 .
  180. Merritt RF, Anastasio N, Zhou J, Cunningham K . ACNP 64th Annual Meeting: Poster Abstracts P292-583: P359. Novel 5-HT2R allosteric ligands demonstrate efficacy in preclinical models of cocaine use disorder . Neuropsychopharmacology . 51 . S1 . 2026 . 0893-133X . 41507445 . 12783661 . 10.1038/s41386-025-02280-3 . 243–409 . January 1, 2027 . 18 January 2026.
  181. Web site: Novel heterocyclic compounds as serotonin (5-ht) 5-ht2a and 5-ht2c receptor positive allosteric modulators . Google Patents . 18 August 2022 . 18 January 2026.
  182. Moya PR, Berg KA, Gutiérrez-Hernandez MA, Sáez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP . Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors . The Journal of Pharmacology and Experimental Therapeutics . 321 . 3 . 1054–1061 . June 2007 . 17337633 . 10.1124/jpet.106.117507 . 11651502 .
  183. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA . Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior . Neuron . 53 . 3 . 439–452 . February 2007 . 17270739 . 10.1016/j.neuron.2007.01.008 . 16309730 . free .
  184. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I . Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells . European Journal of Pharmacology . 594 . 1–3 . 32–38 . October 2008 . 18703043 . 10.1016/j.ejphar.2008.07.040 .
  185. Schmid CL, Raehal KM, Bohn LM . Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo . Proceedings of the National Academy of Sciences of the United States of America . 105 . 3 . 1079–1084 . January 2008 . 18195357 . 2242710 . 10.1073/pnas.0708862105 . free .
  186. Abbas A, Roth BL . Arresting serotonin . Proceedings of the National Academy of Sciences of the United States of America . 105 . 3 . 831–832 . January 2008 . 18195368 . 2242676 . 10.1073/pnas.0711335105 . free . 2008PNAS..105..831A .
  187. Zhang G, Cheng J, McCorvy JD, Lorello PJ, Caldarone BJ, Roth BL, Kozikowski AP . Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications . Journal of Medicinal Chemistry . 60 . 14 . 6273–6288 . July 2017 . 28657744 . 7374938 . 10.1021/acs.jmedchem.7b00584 .
  188. Blier P, El Mansari M . Serotonin and beyond: therapeutics for major depression . Philos Trans R Soc Lond B Biol Sci . 368 . 1615 . 20120536 . 2013 . 23440470 . 3638389 . 10.1098/rstb.2012.0536 .
  189. Pourhamzeh M, Moravej FG, Arabi M, Shahriari E, Mehrabi S, Ward R, Ahadi R, Joghataei MT . The Roles of Serotonin in Neuropsychiatric Disorders . Cell Mol Neurobiol . 42 . 6 . 1671–1692 . August 2022 . 33651238 . 11421740 . 10.1007/s10571-021-01064-9 .
  190. Rothman RB, Baumann MH . Serotonin releasing agents. Neurochemical, therapeutic and adverse effects . Pharmacol Biochem Behav . 71 . 4 . 825–836 . April 2002 . 11888573 . 10.1016/s0091-3057(01)00669-4 .
  191. Rothman RB, Baumann MH . Therapeutic and adverse actions of serotonin transporter substrates . Pharmacol Ther . 95 . 1 . 73–88 . July 2002 . 12163129 . 10.1016/s0163-7258(02)00234-6 .
  192. Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects . Drug Development Research . 51 . 2 . 52–65 . 2000 . 10.1002/1098-2299(200010)51:2<52::AID-DDR2>3.0.CO;2-H . Rothman RB, Baumann MH . 0272-4391 .
  193. Rothman RB, Baumann MH . Therapeutic potential of monoamine transporter substrates . Curr Top Med Chem . 6 . 17 . 1845–1859 . 2006 . 17017961 . 10.2174/156802606778249766 .
  194. Dunlap LE, Andrews AM, Olson DE . Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine . ACS Chem Neurosci . 9 . 10 . 2408–2427 . October 2018 . 30001118 . 6197894 . 10.1021/acschemneuro.8b00155 .
  195. Oeri HE . Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy . J Psychopharmacol . 35 . 5 . 512–536 . May 2021 . 32909493 . 8155739 . 10.1177/0269881120920420 .
  196. Gillman PK . Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review . Headache . 50 . 2 . 264–272 . February 2010 . 19925619 . 10.1111/j.1526-4610.2009.01575.x .
  197. Sun-Edelstein C, Tepper SJ, Shapiro RE . Drug-induced serotonin syndrome: a review . Expert Opin Drug Saf . 7 . 5 . 587–596 . September 2008 . 18759711 . 10.1517/14740338.7.5.587 .
  198. Chiew AL, Isbister GK . [Not Available] . Br J Clin Pharmacol . 91 . 3 . 654–661 . March 2025 . 38926083 . 11862804 . 10.1111/bcp.16152 . French .
  199. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L . Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats . Journal of Nuclear Medicine . 32 . 12 . 2266–2272 . December 1991 . 1744713 .
  200. Lundkvist C, Halldin C, Ginovart N, Nyberg S, Swahn CG, Carr AA, Brunner F, Farde L . [11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography . Life Sciences . 58 . 10 . PL 187-PL 192 . 1996 . 8602111 . 10.1016/0024-3205(96)00013-6 .
  201. Johansen A, Hansen HD, Svarer C, Lehel S, Leth-Petersen S, Kristensen JL, Gillings N, Knudsen GM . The importance of small polar radiometabolites in molecular neuroimaging: A PET study with [<sup>11</sup>C]Cimbi-36 labeled in two positions . Journal of Cerebral Blood Flow and Metabolism . 38 . 4 . 659–668 . April 2018 . 29215308 . 5888860 . 10.1177/0271678x17746179 .
  202. Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y, Snyder AZ . Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography . Biological Psychiatry . 55 . 3 . 217–224 . February 2004 . 14744461 . 10.1016/j.biopsych.2003.08.015 . 24849671 .
  203. Rosier A, Dupont P, Peuskens J, Bormans G, Vandenberghe R, Maes M, de Groot T, Schiepers C, Verbruggen A, Mortelmans L . Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging . Psychiatry Research . 68 . 1 . 11–22 . November 1996 . 9027929 . 10.1016/S0925-4927(96)02806-5 . 32317795 .
  204. Meltzer CC, Smith G, Price JC, Reynolds CF, Mathis CA, Greer P, Lopresti B, Mintun MA, Pollock BG, Ben-Eliezer D, Cantwell MN, Kaye W, DeKosky ST . Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction . Brain Research . 813 . 1 . 167–171 . November 1998 . 9824691 . 10.1016/S0006-8993(98)00909-3 . 21884218 .
  205. Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugbøl S, Madsen K, Frøkjaer V, Martiny L, Paulson OB, Knudsen GM . A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables . NeuroImage . 21 . 3 . 1105–1113 . March 2004 . 15006678 . 10.1016/j.neuroimage.2003.10.046 . 24403109 .
  206. Choi MJ, Lee HJ, Lee HJ, Ham BJ, Cha JH, Ryu SH, Lee MS . Association between major depressive disorder and the -1438A/G polymorphism of the serotonin 2A receptor gene . Neuropsychobiology . 49 . 1 . 38–41 . 2004 . 14730199 . 10.1159/000075337 . 19528052 .
  207. Williams J, Spurlock G, McGuffin P, Mallet J, Nöthen MM, Gill M, Aschauer H, Nylander PO, Macciardi F, Owen MJ . Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group . Lancet . 347 . 9011 . 1294–1296 . May 1996 . 8622505 . 10.1016/s0140-6736(96)90939-3 . 8510590 .
  208. Vaquero-Lorenzo C, Baca-Garcia E, Diaz-Hernandez M, Perez-Rodriguez MM, Fernandez-Navarro P, Giner L, Carballo JJ, Saiz-Ruiz J, Fernandez-Piqueras J, Baldomero EB, de Leon J, Oquendo MA . Association study of two polymorphisms of the serotonin-2A receptor gene and suicide attempts . American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics . 147B . 5 . 645–649 . July 2008 . 18163387 . 10.1002/ajmg.b.30642 . 31504282 .
  209. http://www.schizophreniaforum.org/res/sczgene/geneoverview.asp?geneid=293 Gene Overview of All Published Schizophrenia-Association Studies for HTR2A
  210. Serretti A, Drago A, De Ronchi D . HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies . Current Medicinal Chemistry . 14 . 19 . 2053–2069 . 2007 . 17691947 . 10.2174/092986707781368450 .
  211. Maple AM, Zhao X, Elizalde DI, McBride AK, Gallitano AL . Htr2a Expression Responds Rapidly to Environmental Stimuli in an Egr3-Dependent Manner . ACS Chemical Neuroscience . 6 . 7 . 1137–1142 . July 2015 . 25857407 . 4565721 . 10.1021/acschemneuro.5b00031 .
  212. Williams AA, Ingram WM, Levine S, Resnik J, Kamel CM, Lish JR, Elizalde DI, Janowski SA, Shoker J, Kozlenkov A, González-Maeso J, Gallitano AL . Reduced levels of serotonin 2A receptors underlie resistance of Egr3-deficient mice to locomotor suppression by clozapine . Neuropsychopharmacology . 37 . 10 . 2285–2298 . September 2012 . 22692564 . 3422493 . 10.1038/npp.2012.81 .
  213. Latorre E, Mesonero JE, Harries LW . Alternative splicing in serotonergic system: Implications in neuropsychiatric disorders . Journal of Psychopharmacology . 33 . 11 . 1352–1363 . November 2019 . 31210090 . 10.1177/0269881119856546 . 190531249 .
  214. Spies M, Nasser A, Ozenne B, Jensen PS, Knudsen GM, Fisher PM . Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels . Human Brain Mapping . 41 . 16 . 4518–4528 . November 2020 . 32697408 . 7555071 . 10.1002/hbm.25138 .
  215. Qesseveur G, Petit AC, Nguyen HT, Dahan L, Colle R, Rotenberg S, Seif I, Robert P, David D, Guilloux JP, Gardier AM, Verstuyft C, Becquemont L, Corruble E, Guiard BP . Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach . Neuropharmacology . 105 . 142–153 . June 2016 . 26764241 . 10.1016/j.neuropharm.2015.12.022 . 15031564 .
  216. Ghasemi A, Seifi M, Baybordi F, Danaei N, Samadi Rad B . Association between serotonin 2A receptor genetic variations, stressful life events and suicide . Gene . 658 . 191–197 . June 2018 . 29526601 . 10.1016/j.gene.2018.03.023 . 4854262 .
  217. Videtic A, Pungercic G, Pajnic IZ, Zupanc T, Balazic J, Tomori M, Komel R . Association study of seven polymorphisms in four serotonin receptor genes on suicide victims . American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics . 141B . 6 . 669–672 . September 2006 . 16856120 . 10.1002/ajmg.b.30390 . 9279191 .
  218. Laje G, McMahon FJ . The pharmacogenetics of major depression: past, present, and future . Biological Psychiatry . 62 . 11 . 1205–1207 . December 2007 . 17949692 . 10.1016/j.biopsych.2007.09.016 . 37225993 .
  219. Leamy TE, Connor JP, Voisey J, Young RM, Gullo MJ . Alcohol misuse in emerging adulthood: Association of dopamine and serotonin receptor genes with impulsivity-related cognition . Addictive Behaviors . 63 . 29–36 . December 2016 . 27399274 . 10.1016/j.addbeh.2016.05.008 .
  220. Jakubczyk A, Wrzosek M, Lukaszkiewicz J, Sadowska-Mazuryk J, Matsumoto H, Sliwerska E, Glass J, Burmeister M, Brower KJ, Wojnar M . The CC genotype in HTR2A T102C polymorphism is associated with behavioral impulsivity in alcohol-dependent patients . Journal of Psychiatric Research . 46 . 1 . 44–49 . January 2012 . 21930285 . 3224206 . 10.1016/j.jpsychires.2011.09.001 .
  221. da Silva Junior FC, Araujo RM, Sarmento AS, de Carvalho MM, Fernandes HF, Yoshioka FK, Pinto GR, Motta FJ, Canalle R . The association of A-1438G and T102C polymorphisms in HTR2A and 120 bp duplication in DRD4 with alcoholic dependence in a northeastern Brazilian male population . Gene Reports . 21 . 100889 . December 2020 . 10.1016/j.genrep.2020.100889 . 224859807 .
  222. Land MA, Ramesh D, Miller AL, Pyles RB, Cunningham KA, Moeller FG, Anastasio NC . Methylation Patterns of the HTR2A Associate With Relapse-Related Behaviors in Cocaine-Dependent Participants . Frontiers in Psychiatry . 11 . 532 . 2020-06-10 . 32587535 . 7299072 . 10.3389/fpsyt.2020.00532 . free .
  223. Bolinger AA, Zamora J, Merritt CR, Anastasio NC, Cunningham KA, Zhou J . Discovery of novel serotonin 5-HT2A receptor positive allosteric modulators . 16TH Annual Behavior, Biology, and Chemistry: Translational Research in Substance Use Disorders, San Antonio, Texas | Embassy Landmark | 22-24 March 2024 | date = March 2024 | url = https://ww2.uthscsa.edu/ARTT/BBC/print/2024Program.pdf | quote = Synthesizing and screening novel small molecules, we identified potent positive allosteric modulators (PAMs) of 5-HT2AR. Further analysis and comparison against CNS receptors, channels, and transporters led to the identification of AB0124 a potential candidate with high specificity. This compound has demonstrated functional increases in 5-HT-induced Ca2+ release at the micromolar level for the 5-HT2AR over other serotonin receptors. With promising in vitro pharmacological and physicochemical profiles, our novel 5-HT2AR PAMs hold potential as neurotherapeutics for [cocaine use disorder (CUD)].}}[181]

    Functional selectivity

    5-HT2A-receptor ligands may differentially activate the transductional pathways (see above). Studies evaluated the activation of two effectors, PLC and PLA2, by means of their second messengers. Compounds displaying more pronounced functional selectivity are 2,5-DMA and 2C-N. The former induces IP accumulation without activating the PLA2 mediated response, while the latter elicits AA release without activating the PLC mediated response.[182]

    Recent research has suggested potential signaling differences within the somatosensory cortex between 5-HT2A agonists that produce headshakes in the mouse and those that do not, such as lisuride, as these agents are also non-hallucinogenic in humans despite being active 5-HT2A agonists.[183] [184] One known example of differences in signal transduction is between the two 5-HT2A agonists serotonin and DOI that involves differential recruitment of intracellular proteins called β-arrestins, more specifically arrestin beta 2.[185] [186] Cyclopropylmethanamine derivatives such as (−)-19 have also been shown to act as 5-HT2A/2C agonists with functional selectivity for Gq-mediated signaling compared with β-arrestin recruitment.[187]

    Serotonin-elevating drugs

    Besides direct serotonin 5-HT2A receptor agonists, many drugs elevate serotonin levels and indirectly activate serotonin 5-HT2A receptors.[188] [189] Examples include antidepressants and anxiolytics such as selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and serotonin precursors like tryptophan and 5-hydroxytryptophan (5-HTP). In addition, serotonin releasing agents (SRAs), including appetite suppressants like fenfluramine and chlorphentermine and entactogens like MDMA, elevate serotonin levels and indirectly activate serotonin 5-HT2A receptors similarly.[190] [191] [192] [193] [194] [195] Serotonin 5-HT2A receptor activation may be involved in the therapeutic effects of serotonin-elevating medications and appears to be importantly involved in the subjective effects of SRAs like MDMA. Serotonin-elevating drugs can cause serotonin syndrome under certain circumstances, for instance in overdose or with combination of multiple serotonergic drugs, and the serotonin 5-HT2A receptor appears to be a key serotonin receptor in mediating this syndrome.[196] [197] [198]

    Methods to analyse the receptor

    The receptor can be analysed by neuroimaging, radioligand, genetic analysis, measurements of ion flows, and other ways.

    Neuroimaging

    The 5-HT2A receptors may be imaged with PET-scanners using the fluorine-18-altanserin,[199] MDL 100,907[200] or [<sup>11</sup>C]Cimbi-36[201] radioligands that binds to the neuroreceptor, e.g., one study reported a reduced binding of altanserin particularly in the hippocampus in patients with major depressive disorder.[202]

    Altanserin uptake decreases with age reflecting a loss of specific 5-HT2A receptors with age.[203] [204] [205]

    Other

    Western blot with an affinity-purified antibody and examination of 5-HT2A receptor protein samples by electrophoresis has been described. Immunohistochemical staining of 5-HT2A receptors is also possible.

    Clinical significance

    Associations with psychiatric disorders

    Several studies have seen links between the -1438G/A polymorphism and mood disorders, such as major depressive disorder.[206] and a strong link with an odds ratio of 1.3 has been found between the T102C polymorphism and schizophrenia.[207]

    The T102C polymorphism has also been studied in relation to suicide attempts, with a study finding excess of the C/C genotype among the suicide attempters.[208] A number of other studies were devoted to finding an association of the gene with schizophrenia, with diverging results.[209]

    These individual studies may, however, not give a full picture: A review from 2007 looking at the effect of different SNPs reported in separate studies stated that "genetic association studies [of HTR2A gene variants with psychiatric disorders] report conflicting and generally negative results" with no involvement, small or a not replicated role for the genetic variant of the gene.[210]

    Polymorphisms in the promoter gene coding Early growth response 3 (EGR3) are associated with schizophrenia. Studies have demonstrated a relationship between EGR3 and HTR2A, and schizophrenia-like behaviors in transgenic animals.[211] [212] Exactly how these results translate over to further biopsychological understanding of schizophrenia is still widely debated.[213] [214] There is some evidence that dysfunction of HTR2A can impact pharmacological interventions.[215]

    Several studies have assessed a relationship between 5-hydroxytryptamine (serotonin) 2A receptor (5-HTR2A) gene polymorphisms with an increased risk of suicidal behavior. One study revealed that T102C polymorphism is associated with suicidal behavior[216] but other studies failed to replicate these findings and found no association between polymorphism and suicidal behavior.[217]

    Treatment response

    Genetics seems also to be associated to some extent with the amount of adverse events in treatment of major depression disorder.[218]

    Associations with substance abuse

    Polymorphisms in the 5-HT2A receptor coding gene HTR2A (rs6313 and s6311) have been shown to have conflicting associations with alcohol misuse. For example, A polymorphism in the 5-HT2A receptor coding gene HTR2A (rs6313) was reported to predict lower positive alcohol expectancy, higher refusal self-efficacy, and lower alcohol misuse in a sample of 120 young adults. However, this polymorphism did not moderate the linkages between impulsivity, cognition, and alcohol misuse.[219] There are conflicting results as other studies have found associations between T102C polymorphisms alcohol misuse.[220] [221]

    Drug impact on gene expression

    There is some evidence that methylation patterns may contribute to relapse behaviors in people who use stimulants.[222] In mice, psychotropic drugs such as DOI, LSD, DOM, and DOB which produced differing transcriptional patterns among several different brain regions.

    See also

    Further reading

    • Perez-Aguilar JM, Shan J, LeVine MV, Khelashvili G, Weinstein H . A functional selectivity mechanism at the serotonin-2A GPCR involves ligand-dependent conformations of intracellular loop 2 . Journal of the American Chemical Society . 136 . 45 . 16044–16054 . November 2014 . 25314362 . 4235374 . 10.1021/ja508394x . 2014JAChS.13616044P .

    External links

    • Web site: 5-HT2A . IUPHAR Database of Receptors and Ion Channels . International Union of Basic and Clinical Pharmacology .
    .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "5-HT2A receptor".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2026, A B Cryer, All Rights Reserved. Cookie policy.